fr en

Reagents and instruments for immunology, cell biology and molecular biology.

L-Ascorbic acid [50-81-7]

Print

Cat# HY-B0166-1g

Size : 1g

Contact local distributor :

Phone : +1 850 650 7790

Brand : MedChemExpress

Request more information

Contact local distributor :

Phone : +1 850 650 7790

Description

L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Ca_v3.2 channels with an IC₅₀ of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor^[1]^[2]^[3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells^[4].

IC₅₀ & Target

T-type calcium channel

Microbial Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
CFPAC-1	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human CFPAC-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
Erythrocyte	EC₅₀	119.87 μg/mL Compound: Ascorbic acid	Antioxidant activity in erythrocytes assessed as inhibition of hemolysis Antioxidant activity in erythrocytes assessed as inhibition of hemolysis	[PMID: 22677320]
Erythrocyte	EC₅₀	96.625 μg/mL Compound: Ascorbic acid	Hemolysis of human erythrocytes after 30 mins by spectrophotometry Hemolysis of human erythrocytes after 30 mins by spectrophotometry	[PMID: 23811092]
HCT-116	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human HCT116cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
HEK293	EC₅₀	0.5 nM Compound: Ascorbic acid	Agonist activity at human adrenergic alpha2B receptor expressed in HEK293 cells coexpressing Gqi5 protein by FLIPR assay Agonist activity at human adrenergic alpha2B receptor expressed in HEK293 cells coexpressing Gqi5 protein by FLIPR assay	[PMID: 19243956]
HEK293	EC₅₀	156 μM Compound: 54670067	Substrate uptake and inhibition of the Na(+)/L-Ascorbic Acid Transporter 1 (SVCT1, SLC23A1) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC23A1 cells (PubChem AID: 1794810) Substrate uptake and inhibition of the Na(+)/L-Ascorbic Acid Transporter 1 (SVCT1, SLC23A1) as assessed by the fluorescent FLIPR membrane potential dye in HEK-293 JumpIN-SLC23A1 cells (PubChem AID: 1794810)	10.5281/zenodo.7360349
HeLa	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
HepG2	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
HFF	IC₅₀	>100 μM Compound: L-ASA	Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
HL-60	IC₅₀	0.01 μM Compound: Vitamin C	Antioxidant activity in human HL60 cells assessed as inhibition of relative oxygen species generation by DCFH-DA method Antioxidant activity in human HL60 cells assessed as inhibition of relative oxygen species generation by DCFH-DA method	[PMID: 19555121]
HL-60	IC₅₀	10.2 μM Compound: Vitamin C	Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay	[PMID: 16562834]
HL-60	IC₅₀	9.7 μM Compound: Vitamin C	Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay	[PMID: 12762791]
J774.A1	IC₅₀	>100 μM Compound: AA	Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis	[PMID: 33422907]
MCF7	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]
RD	EC₅₀	>2270 μM Compound: AA	Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Herpes simplex virus type 1 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 22390834]
SW-620	IC₅₀	>100 μM Compound: L-ASA	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31586832]

In Vitro

The anti-cancer effects of L-Ascorbic acid are determined by sodium-dependent vitamin C transporter 2 (SVCT-2), a transporter of L-ascorbic acid. L-Ascorbic acid (0.1 μM-2 mM) exhibits anti-cancer effects according to SVCT-2 expression and L-ascorbic acid uptake. Human colorectal cancer cell lines displays differential responses to L-ascorbic acid, primarily depending on the expression level of SVCT-2^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	High SVCT-2 expressing cell lines Sw620, Sw480, LoVo, SNU-C4; Low SVCT-2 expressing cell lines HCT15, HCT116, DLD-1, CoLo-205
Concentration:	0, 0.1 μM, 1 μM, 10 μM, 0.1 mM, 0.5 mM, 1 mM, and 2 mM
Incubation Time:	24 hours
Result:	Some high SVCT-2 expressing cancer cells demonstrated a dramatic cell-autonomous inhibitory effect of L-ascorbic acid. Low SVCT-2 expressing cell lines showed biphasic responses to L-ascorbic acid.

Western Blot Analysis^[4]

Cell Line:	Sw620, Sw480, LoVo, SNU-C4, HCT15, HCT116, DLD-1, CoLo-205 cell lines
Concentration:	1 mM
Incubation Time:
Result:	The cell lines showed different levels of SVCT-2 expression in western blot analyses: Sw620, Sw480, and Lovo expressed high levels of SVCT-2 whereas HCT116, HCT15, and DLD-1 expressed low levels.

In Vivo

L-Ascorbic acid/Tolbutamide produces hypoglycaemic activity in a dose dependant manner in normal (60 mg/kg) and diabetic (40 mg/kg) condition. In the presence of L-ascorbic acid, Tolbuatmide (20 mg/kg) produces early onset of action and maintained for longer period compared to Tolbutamide matching control^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal rats:Albino rats of either sex weighing between 125-175 g^[5]
Dosage:	Group I received L-ascorbic acid 60 mg/kg, Group II received Tolbutamide 20 mg/kg and Group III was given L-ascorbic acid (60 mg/kg) prior to the administration of tolbutamide 20 mg/kg
Administration:	Administered orally
Result:	L-ascorbic acid at the dose of 60 mg/kg produced 50.91% blood glucose reduction at 0.5 h and 20 mg/kg body weight of Tolbutamide produced 33% at 4 h as peak effects. In the presence of L-ascorbic acid (60 mg/kg), the action of Tolbutamide was early in onset and maintained for 6 h.

Animal Model:	Diabetic rats:Albino rats of either sex weighing between 125 to 175 g were fasted overnight before injection with Alloxan^[5]
Dosage:	Group I received L-ascorbic acid 40 mg/kg and Group II received Tolbutamide 20 mg/kg while Group III was given L-ascorbic acid 40 mg/kg prior to Tolbutamide administration (20 mg/kg).
Administration:	Oral administration
Result:	L-ascorbic acid (40 mg/kg alone) produced 42.53% blood glucose reduction at 1.5 h and Tolbutamide 20 mg/kg produced 45.09 at 4 h. Administration of L-ascorbic acid 40 mg/kg body weight prior to Tolbutamide produced antidiabetic activity at 0.5 h and was maintained for 6 h.

Molecular Weight

176.12

Formula

C₆H₈O₆

CAS No.

50-81-7

Appearance

Solid

Color

White to off-white

SMILES

OC([C@@]1(13)[C@H](CO)O)=C(O)C(O1)=O

Structure Classification

Others

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

RT, protect from light

In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (567.79 mM)

DMSO : 100 mg/mL (567.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.6779 mL	28.3897 mL	56.7795 mL
5 mM	1.1356 mL	5.6779 mL	11.3559 mL
10 mM	0.5678 mL	2.8390 mL	5.6779 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (28.39 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (28.39 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (28.39 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (567.79 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.97%

Data Sheet (281 KB) SDS (394 KB)

COA (252 KB) RP-HPLC (205 KB) LCMS (92 KB) Elemental Analysis Report (111 KB)

Handling Instructions (2659 KB)

References

[1]. Sebastian J Padayatty, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003 Feb;22(1):18-35. [Content Brief]

[2]. Michael T Nelson, et al. Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate. J Neurosci. 2007 Nov 14;27(46):12577-83. [Content Brief]

[3]. Aleksander Hinek, et al. Sodium L-ascorbate enhances elastic fibers deposition by fibroblasts from normal and pathologic human skin. J Dermatol Sci. 2014 Sep;75(3):173-82. [Content Brief]

[4]. Sungrae Cho, et al. Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression. Sci Rep. 2018 Jul 27;8(1):11372. [Content Brief]

[5]. Satyanarayana Sreemantula, et al. Influence of antioxidant (L- ascorbic acid) on tolbutamide induced hypoglycaemia/antihyperglycaemia in normal and diabetic rats. BMC Endocr Disord. 2005 Mar 3;5(1):2. [Content Brief]

You might also be interested by the following products:

Cat#

Description

Cond.

Price Bef. VAT

100-01-10UG

RH BDNF

10UG

100-01-100UG

RH BDNF

100UG

GK002-SC

GeneQuery™ Human Pluripotent Stem Cell qPCR Array Kit

1kit

L-Ascorbic acid [50-81-7]

Cat# HY-B0166-1g

Contact local distributor :

Brand : MedChemExpress

Contact local distributor :

L-Ascorbic acid Related Antibodies

You might also be interested by the following products: